Generics Firms Could Pay €20 Million a Year for Pharmacovigilance, EGA - European Generic Medicines Association Says
Proposed EMA pharmacovigilance fees are too high and place a disproportionate burden on generics firms according to the European Generic Medicines Association (EGA).